Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

107

Participants

Timeline

Start Date

March 21, 2011

Primary Completion Date

August 20, 2016

Study Completion Date

November 3, 2016

Conditions
Recurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal Carcinoma
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Fosbretabulin Tromethamine

Given IV

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (51)

19111

Fox Chase Cancer Center, Philadelphia

19718

Christiana Care Health System-Christiana Hospital, Newark

19958

Beebe Medical Center, Lewes

21215

Sinai Hospital of Baltimore, Baltimore

21237

MedStar Franklin Square Medical Center/Weinberg Cancer Institute, Baltimore

23298

Virginia Commonwealth University/Massey Cancer Center, Richmond

27710

Duke University Medical Center, Durham

28204

Novant Health Presbyterian Medical Center, Charlotte

29615

Greenville Health System Cancer Institute-Eastside, Greenville

30501

Northeast Georgia Medical Center-Gainesville, Gainesville

31404

Memorial Health University Medical Center, Savannah

33133

Mercy Hospital, Miami

39216

Saint Dominic-Jackson Memorial Hospital, Jackson

University of Mississippi Medical Center, Jackson

44111

Cleveland Clinic Cancer Center/Fairview Hospital, Cleveland

44124

Hillcrest Hospital Cancer Center, Mayfield Heights

44304

Summa Akron City Hospital/Cooper Cancer Center, Akron

45219

University of Cincinnati/Barrett Cancer Center, Cincinnati

46202

Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis

46260

Saint Vincent Hospital and Health Care Center, Indianapolis

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

49007

Bronson Methodist Hospital, Kalamazoo

West Michigan Cancer Center, Kalamazoo

49048

Borgess Medical Center, Kalamazoo

52242

University of Iowa/Holden Comprehensive Cancer Center, Iowa City

54143

Bay Area Medical Center, Marinette

54221

Holy Family Memorial Hospital, Manitowoc

54301

Saint Vincent Hospital Cancer Center Green Bay, Green Bay

54303

Green Bay Oncology Limited at Saint Mary's Hospital, Green Bay

57104

Sanford Cancer Center Oncology Clinic, Sioux Falls

60521

Sudarshan K Sharma MD Limited-Gynecologic Oncology, Hinsdale

60637

University of Chicago Comprehensive Cancer Center, Chicago

63110

Washington University School of Medicine, St Louis

73104

University of Oklahoma Health Sciences Center, Oklahoma City

80033

SCL Health Lutheran Medical Center, Wheat Ridge

80218

Presbyterian - Saint Lukes Medical Center - Health One, Denver

80907

Penrose-Saint Francis Healthcare, Colorado Springs

83706

Saint Alphonsus Cancer Care Center-Boise, Boise

85013

Saint Joseph's Hospital and Medical Center, Phoenix

89169

Women's Cancer Center of Nevada, Las Vegas

90048

Cedars Sinai Medical Center, Los Angeles

91505

Providence Saint Joseph Medical Center/Disney Family Cancer Center, Burbank

92093

UC San Diego Moores Cancer Center, La Jolla

94520

John Muir Medical Center-Concord Campus, Concord

95816

Sutter Medical Center Sacramento, Sacramento

06102

Hartford Hospital, Hartford

04102

Maine Medical Center-Bramhall Campus, Portland

01605

University of Massachusetts Memorial Health Care, Worcester

02905

Women and Infants Hospital, Providence

57117-5134

Sanford USD Medical Center - Sioux Falls, Sioux Falls

54301-3526

Green Bay Oncology at Saint Vincent Hospital, Green Bay

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

NRG Oncology

OTHER

lead

National Cancer Institute (NCI)

NIH

NCT01305213 - Bevacizumab With or Without Fosbretabulin Tromethamine in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer | Biotech Hunter | Biotech Hunter